- Advertise
- Contact Us
- Contribute
- Editorial Info
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Personal Information
- About Us
© 2023 MJH Life Sciences™ and Endocrinology Network. All rights reserved.
Osteoporosis
The Endocrinology Network® Osteoporosis clinical resource center is our hub for the latest in bone health and management of fracture risk. With a fracture causing significant increases in risk of mortality, management of osteoporosis represents a crucial aspect of care. This page will offer the latest information related to FDA approvals, new studies, and guideline updates pertaining to diagnosis and management of osteoporosis.
Abaloparatide Receives FDA Approval for Osteoporosis in Men
December 20, 2022
Announced by Radius Health on December 20, the US FDA approval for abaloparatide (Tymlos) indicates the agent as a treatment to increase bone density in men with osteoporosis at high risk of fracture or in patients who have failed or are intolerant to other available osteoporosis therapy.
Cancer Survivors Face Heightened Risk of Bone Fractures
November 03, 2022
An analysis of data from the Cancer Prevention Study-II suggests cancer survivors had a more than doubling in risk of frailty-related bone fractures than their counterparts without cancer.
Study Finds Global Hip Fractures Expected to Double by 2050
September 12, 2022
A study presented at ASBMR 2022 leveraging data from more than a dozen countries details trends in hip fracture incidence and projects potential incidence increases by 2050.
Vitamin D Supplements Do Not Reduce Fracture Risk in Older Adults
July 27, 2022
An ancillary study of the landmark VITAL trial provides clinicians with evidence related to the lack of reduction in fracture risk observed with vitamin D3 supplementation in older adults.
Study Compares Fracture Risk Among Antidiabetes Medication Regimens
June 27, 2022
An analysis of real-world data from more than 6500 patients suggests insulin users had a greater risk of fracture than patients using metformin, but this became attenuated among patients using a combination of insulin and metformin.
Parathyroidectomy Can Reduce Adverse Outcomes Risk in Primary Hyperparathyroidism
June 20, 2022
Data from Sweden national registers provide insight into the increased risk of adverse outcomes, including fracture, cardiovascular events, and mortality risk, associated with primary hyperparathyroidism as well as the apparent reductions in risk achieved by undergoing parathyroidectomy.
No Increased Risk of Fracture with SGLT2 Inhibitors in Diabetic Kidney Disease, Study Finds
May 27, 2022
Analysis of data from more than 75k patients with diabetes in Canada suggests use of SGLT2 inhibitors was not associated with an increased fracture risk compared with DPP-4 inhibitors among patients with diabetic kidney disease.
Exercise Program Following Hip Fracture Linked to Improved Functional Ability in Older Adults
May 18, 2022
A secondary analysis of the HIPFRA trial indicates participation in a home-based exercise program was associated with increased functional ability and physical performance in adult patients recovering from hip fracture.
Calcium Supplementation Could Increase Risk of Death in Older Adults with Cardiovascular Disease
April 28, 2022
An analysis of data from a Cleveland Clinic database indicates calcium supplementation in older adults with aortic stenosis was linked to an increased risk of mortality and worsening aortic stenosis.
Endocrine Month in Review: April 2022
April 23, 2022
Our endocrine month in review spotlights the most popular articles from the past month. This month's top articles include a multipart video series, new diabetes, information on osteoporosis, and more!